Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: Follow-up through Month 48 in a Phase III randomized study

We previously reported higher anti-HPV-16 and -18 immune responses induced by HPV-16/18 vaccine compared with HPV-6/11/16/18 vaccine at Month 7 (one month after completion of full vaccination series) in women aged 18–45 y in an observer-blind study NCT00423046; the differences of immune response mag...

Descripción completa

Detalles Bibliográficos
Autores principales: Einstein, Mark H, Levin, Myron J, Chatterjee, Archana, Chakhtoura, Nahida, Takacs, Peter, Catteau, Grégory, Dessy, Francis J, Moris, Philippe, Lin, Lan, Struyf, Frank, Dubin, Gary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2014
Materias:
HPV/Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514093/
https://www.ncbi.nlm.nih.gov/pubmed/25483700
http://dx.doi.org/10.4161/hv.36117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514093/
https://www.ncbi.nlm.nih.gov/pubmed/25483700
http://dx.doi.org/10.4161/hv.36117

Ejemplares similares